Uses
Moxidectin is a
second generation macrocyclic lactone of the milbemycin family.
For the treatment
and control of adult and larval stages of important internal parasites
including encysted inhibited EL3 and developing intramucosal L4 larval
stages of small redworms, arterial stages of large redworms and bots
in horses and ponies with a single dose.
EQUEST Oral Gel, at
the recommended dosage level of 400 mcg moxidectin per kg bodyweight,
provides effective control of moxidectin sensitive strains of the
following parasites of horses and ponies:
Large strongyles:
Strongylus vulgaris (adults and arterial stages)
Strongylus edentatus (adults and visceral stages)
Triodontophorus brevicauda (adults)
Triodontophorus serratus (adults)
Triodontophorus tenuicollis (adults)
Small strongyles
(adults and intraluminal larval stages):
Cyathostomum spp.
Cylicocyclus spp.
Cylicostephanus spp.
Cylicodontophorus spp.
Gyalocephalus spp.
EQUEST Oral Gel is
effective against (developing) intramucosal L4 stages of small
strongyles. At eight weeks after treatment early (hypobiotic) EL3
stages of small strongyles are eliminated.
EQUEST Oral Gel is
effective against benzimidazole resistant strains of cyathostomes.
Ascarids:
Parascaris equorum (adult and larval stages)
Other species:
Oxyuris equi (adult and larval stages)
Habronema muscae (adults)
Gasterophilus intestinalis (L2, L3)
Gasterophilus nasalis (L2, L3)
Strongyloides westeri (adults)
Trichostrongylus axei
EQUEST Oral Gel has
a persistent effect in preventing infection by small strongyles for 2
weeks after dosing and suppresses the presence of small strongyle eggs
in the dung for 90 days.
Pharmaceutical
precautions
After opening, use
within 6 months.
Do not store above
25°C.
Keep the syringe in
the carton.
After first use
record the date to be disposed on the label space provided.